BOSTON & PERTH, Australia--(BUSINESS WIRE)--pSivida Limited (NASDAQ:PSDV)(ASX:PSD)(Xetra:PSI) today announced that it closed the second tranche of its previously reported registered direct offering. The second part of the closing related to the sale of 5,200,000 units at a price of US$1.25 (A$1.46) per unit to Pfizer Inc. in accordance with the terms of the Collaborative Research and License Agreement, dated as of April 3, 2007, between the Company and Pfizer. Net of placement agents’ commissions, the Company received approximately US$6.0 million (A$7.0 million) in proceeds from the second tranche of the offering and approximately US$16.7 million (A$19.5 million) in the aggregate offering proceeds. Since entering into the Collaborative Research and License Agreement, Pfizer has invested a total of US$11.5 million (approximately A$13.7 million) in pSivida’s equity and is pSivida's largest shareholder, holding approximately 10.2% of pSivida’s outstanding equity.
